| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Imatinib | FIMM | pan-cancer | AAC | -0.013 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | AP-24534 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | GW-2580 | GDSC1000 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Roscovitine | GDSC1000 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | -0.0022 | 0.9 |
| mRNA | BI-2536 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | -0.011 | 0.9 |
| mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |